๐ฐ Allogene News
Allogene News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Allogene. Real-time updates on events, politics, business and more.
January 5, 2024
Gene editing company, Allogene Therapeutics, Inc. (ALLO), Friday announced its decision to cut down its workforce by 22% in a move to focus on developing its blood cancer therapy.
June 5, 2023
SOUTH SAN FRANCISCO - Allogene Therapeutics, Inc. , a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer, today presented long-term follow up... | June 5, 2023
June 4, 2023
Long Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrate Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Similar to Approved Autologous Therapies Presentation Focused
May 24, 2023
SOUTH SAN FRANCISCO, Calif., May 24, 2023 -- Allogene Therapeutics, Inc. , a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer, today... | May 24, 2023
January 23, 2023
NEW YORK, Jan. 22, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers...
April 27, 2022
Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET SOUTH SAN FRANCISCO, Calif., April 27, 2022 -- Allogene Therapeutics, Inc. , a clinical-stage biotechnology company pioneering the... | April 27, 2022
December 15, 2021
Several startups are raising interestโand dollarsโto support innovative strategies for developing cell therapies to treat solid tumors. But their task is far from easy, with a combination of logistical hurdles and safety issues threatening to slow their progress.
November 3, 2021
It still feels as if the use of cell therapy is a fresh innovation, but inertia is the enemy of progress, and next-gen approaches are already here.
October 8, 2021
By Chris Wack Allogene Therapeutics Inc. shares fell 38% to $15 in premarket trading after the company said the U.S. Food and Drug Administration put a hold on AlloCAR T clinical trials... | October 8, 2021
October 8, 2021
Item 8.01 Other Events. On October 7, 2021, Allogene Therapeutics, Inc. reported that, following a report of a chromosomal abnormality in ALLO-501A chimeric antigen receptor T cells in a patient... | October 8, 2021